Diabetes and foot infection: More than double trouble

Diabetes/Metabolism Research and Reviews

Volumn 28, Issue SUPPL. 1, 2012, Pages 46-53

  Richard, Jean Louis ^a   Lavigne, Jean Philippe ^b,c   Sotto, Albert ^b,c  

^a NÎMES UNIVERSITY HOSPITAL   (France)

^b DEPARTMENT OF NEUROLOGY   (France)

^c UNIV MONTPELLIER   (France)

Author keywords

Biofilm; Diabetic foot; Immunopathy; Infection; Neuropathy; Virulence

Indexed keywords

ARTERIOVENOUS SHUNT; AXOPLASM FLOW; BACTERIAL COLONIZATION; BACTERIAL VIRULENCE; BACTERIUM ISOLATION; BIOFILM; CAENORHABDITIS ELEGANS; DIABETIC ANGIOPATHY; DIABETIC FOOT; DIABETIC NEUROPATHY; DIABETIC PATIENT; DISEASE COURSE; DNA MICROARRAY; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; IONTOPHORESIS; MULTIPLEX POLYMERASE CHAIN REACTION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PERIPHERAL OCCLUSIVE ARTERY DISEASE; POLYMORPHONUCLEAR CELL; PREVALENCE; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; QUORUM SENSING; RESPIRATORY BURST; REVIEW; SCANNING ELECTRON MICROSCOPY; SENSORIMOTOR NEUROPATHY; STAPHYLOCOCCUS AUREUS; WOUND HEALING;

DIABETES COMPLICATIONS; DIABETES MELLITUS; DIABETIC FOOT; HUMANS; WOUND INFECTION;

EID: 84856181527     PISSN: 15207552     EISSN: 15207560     Source Type: Journal    
DOI: 10.1002/dmrr.2234     Document Type: Review

References (63)

1. Prompers L, Huijberts M, Schaper N, et al. Resource utilisation and costs associated with the treatment of diabetic foot ulcers. Prospective data from the Eurodiale study. Diabetologia 2008; 51: 1826-1834.
2. Lavery LA, Armstrong DG, Wunderlich RP, Boulton AJM, Tredwell JM. Diabetic foot syndrome: evaluating the prevalence and incidence of foot pathology in Mexican Americans and non-Hispanic whites from a diabetes disease management cohort. Diabetes Care 2003; 26: 1435-1438.
3. Lavery LA, Armstrong DG, Wunderlich RP, Mohler MJ, Wendel CS, Lipsky BA. Risk factors for foot infections in individuals with diabetes. Diabetes Care 2006; 29: 1288-1293.
4. Moutschen MP, Scheen AJ, Lefebvre PJ. Impaired immune responses in diabetes mellitus: analysis of the factors and mechanisms involved. Relevance to the increased susceptibility of diabetic patients to specific infections. Diabetes Metab 1992; 18: 187-201.
5. Marhoffer W, Stein M, Maeser E, Federlin K. Impairment of polymorphonuclear leukocyte function and metabolic control of diabetes. Diabetes Care 1992; 15: 256-260.
6. Geerlings SE, Hoepelman AI. Immune dysfunction in patients with diabetes mellitus (DM). FEMS Immunol Med Microbiol 1999; 26: 259-265.
7. Witko-Sarsat V, Rieu P, Descamps-Latscha B, Lesavre P, Halbwachs-Mecarelli L. Neutrophils: molecules, functions and pathophysiological aspects. Lab Invest 2000; 80: 617-653.
8. Gallacher SJ, Thomson G, Fraser WD, Fisher BM, Gemmell CG, MacCuish AC. Neutrophil bactericidal function in diabetes mellitus: evidence for association with blood glucose control. Diabet Med 1995; 12: 916-920.
9. Delamaire M, Maugendre D, Moreno M, Le Goff M-C, Allanic H, Genetet B. Impaired leucocyte functions in diabetic patients. Diabet Med 1997; 14: 29-34.
10. Wiernsperger NF. Oxidative stress as a therapeutic target in diabetes: revisiting the controversy. Diabetes Metab 2003; 29: 579-585.
11. Larijani B, Shooshtarizadeh P, Mosaffa P, Heshmat R. Polymorphonuclear leucocyte respiratory burst activity correlates with serum zinc level in type 2 diabetic patients with foot ulcers. Br J Biomed Sci 2007; 64: 13-17.
12. Sato N, Shumizu H, Suwa K, Shumomura Y, Kobayashi II, Mori M. MPO activity and generation in leukocytes from poorly controlled diabetic patients. Diabetes Care 1992; 15: 1050-1052.
13. Muchová J, Liptáková A, Országhová Z, et al. Antioxidant systems in polymorphonuclear leucocytes in type 2 diabetes mellitus. Diabet Med 1999; 16: 74-78.
14. Wykretowicz A, Wierusz-Wysocka B, Wysocki J, Szczepanik A, Wysocki H. Impairment of the oxygen-dependent microbicidal mechanisms of polymorphonuclear neutrophils in patients with type 2 diabetes is not associated with increased susceptibility to infection. Diabetes Res Clin Pract 1993; 19: 195-201.
15. Rich J, Lee JC. The pathogenesis of Staphylococcus aureus infection in the diabetic NOD mouse. Diabetes 2005; 54: 2904-2910.
16. db mice to infection by Staphylococcus aureus. Infect Immun 2009; 77: 1008-1014.
17. Vinik AI, Maser RE, Mitchell BD, Freeman R. Diabetic autonomic neuropathy. Diabetes Care 2003; 26: 1553-1579.
18. Braverman IM. The cutaneous microcirculation. J Invest Dermatol Symp Proc 2000; 5: 3-9.
19. Vinik AI, Erbas T, Sun Park T, Stansberry KB, Scanelli JA, Pittenger GL. Dermal neurovsacular dysfunction in type 2 diabetes. Diabetes Care 2001; 24: 1468-1475.
20. Edmonds ME, Robert VC, Watkins PJ. Blood flow in the diabetic neuropathic foot. Diabetologia 1982; 22: 9-15.
21. Zimny S, Dessel F, Ehren M, Pfohl M, Schatz H. Early detection of microcirculatory impairment in diabetic patients with foot at risk. Diabetes Care 2001; 24: 1810-1814.
22. Durnett Richardson J, Vasko MR. Cellular mechanisms of neurogenic inflammation. J Pharmacol Exp Ther 2002; 302: 839-845.
23. Shepherd AJ, Downing JEG, Miyan JA. Without nerves, immunology remains incomplete - in vivo veritas. Immunology 2005; 116: 145-163.
24. Roosterman D, Goerge T, Schneider SW, Bunnett NW, Steinhoff M. Neuronal control of skin function: the skin as a neuroimmunonendocrine organ. Physiol Rev 2006; 86: 1309-1379.
25. Peters EMJ, Ericson ME, Hosoi J, et al. Neuropeptide control mechanisms in cutaneous biology: physiological and clinical significance. J Invest Dermatol 2006; 126: 1937-1947.
26. Krishnan STM, Rayman G. The LDIflare. A novel test of C-fiber function demonstrates early neuropathy in type 2 diabetes. Diabetes Care 2004; 27: 2930-2935.
27. Schaper NC, Huijberts N, Pickwell K. Neurovascular control and neurogenic inflammation in diabetes. Diabetes Metab Res Rev 2008; 24(Suppl 1): S40-S44.
28. Peters EJ, Lavery LA, Armstrong DG. Diabetic lower extremity infection. Influence of physical, psychological, and social factors. J Diabetes Complications 2005; 19: 107-112.
29. Prompers N, Schaper N, Apelqvist J, et al. Prediction of outcome in individuals with diabetic foot ulcers: focus on the differences in individuals with and without peripheral arterial disease. The EURODIALE study. Diabetologia 2008; 51: 747-755.
30. Raymakers JT, Houben AJ, van der Heyden JJ, Tordoir JH, Kitslaar PJ, Schaper NC. The effect of diabetes and severe ischaemia on the penetration of ceftazidime into tissues of the limb. Diabet Med 2001; 18: 229-234.
31. Flynn MD, Tooke JE. Aetiology of diabetic foot ulceration: a role for the microcirculation? Diabet Med 1992; 8: 320-322.
32. Dinh T, Veves A. Microvascular changes in the diabetic foot. In The Diabetic Foot (2nd ed. edn), Veves A, Giurini JM, LoGerfo FW (eds). Humana Press: Totowa, 2006; 131-145.
33. Rayman G, Malik RA, Sharma AK, Day JL. Microvascular response to tissue injury and capillary ultrastructure in the foot skin of type I diabetic patients. Clin Sci 1995; 89: 467-474.
34. Jaap AJ, Tooke JE. Is microvascular disease important in the diabetic foot?. In The Foot in Diabetes (2nd ed. edn), Boulton AJM, Connor H, Cavanagh PR (eds). Wiley: Chichester, 1994; 49-56.
35. Veves A, Akbari CM, Primavera J, et al. Endothelial dysfunction and the expression of endothelial nitric oxide synthetase in diabetic neuropathy, vascular disease and foot ulceration. Diabetes 1998; 38: 457-463.
36. Goldman FG. Deep space infections in the diabetic patients. J Am Podiatr Med Assoc 1987; 77: 431-443.
37. van Baal JG. Surgical treatment of the infected diabetic foot. Clin Infect Dis 2004; 39(Suppl 2): S123-S128.
38. Lee BY, Guerra VJ, Civelek B. Compartment syndrome in the diabetic foot. Adv Wound Care 1995; 3: 36-46.
39. Rauwerda JA. Foot debridement: anatomic knowledge is mandatory. Diabetes Metab Res Rev 2000; 16(Suppl 1): S23-S26.
40. Bendy RH, Nuccio PA, Wolfe E, et al. Relationship of quantitative wound bacterial counts to healing of decubitii: effect of topical gentamicin. Antimicrob Agents Chemother 1964; 4: 147-155.
41. Bowler PG, Duerden BI, Armstrong DG. Wound microbiology and associated approaches to wound management. Clin Microbiol Rev 2001; 14: 244-269.
42. Xu L, McLennan SV, Lo L, et al. Bacterial load predicts healing rate in neuropathic diabetic foot ulcers. Diabetes Care 2007; 30: 378-380.
43. Dow G, Browne A, Sibbal RG. Infection in chronic wounds: controversies in diagnosis and treatment. Ostomy Wound Manage 1999; 45: 23-40.
44. Robson MC, Heggers JP. Delayed wound closures based on bacterial counts. J Surg Oncol 1970; 2: 379-383.
45. Monecke S, Ehricht R. Rapid genotyping of methicillin-resistant Staphylococcus aureus (MRSA) isolates using miniaturized oligonucleotide arrays. Clin Microbiol Infect 2005; 11: 825-833.
46. Sotto A, Richard J-L, Jourdan N, et al. Miniaturized oligonucleotide arrays. A new tool for discriminating colonization from infection due to Staphylococcus aureus in diabetic foot ulcers. Diabetes Care 2007; 30: 2051-2056.
47. Sotto A, Lina G, Richard J-L, et al. Virulence potential of Staphylococcus aureus strains isolated from diabetic foot ulcers. A new paradigm. Diabetes Care 2008; 31: 2318-2324.
48. Lavigne J-P, Blanc-Potard A-B, Bourg C, O'Callaghan D, Sotto A. Caenorhabditis elegans: modèle d'étude in vivo de la virulence bactérienne [Caenorhabditis elegans: in vivo study model of bacterial virulence]. Pathol Biol 2006; 54: 439-446.
49. Sifri CD, Begun J, Ausubel FM, Calderwood SB. Caenorhabditis elegans as a model host for Staphylococcus aureus pathogenesis. Infect Immun 2003; 71: 2208-2217.
50. Meekera ND, Trede NS. Immunology and zebrafish: spawning new models of human disease. Dev Comp Immunol 2008; 32: 745-757.
51. Prajsnar TK, Cunliffe VT, Foster NJ, Renshaw SA. A novel vertebrate model of Staphylococcus aureus infection reveals phagocyte-dependent resistance of zebrafish to non-host specialized pathogens. Cell Microbiol 2008; 10: 2312-2325.
52. Percival SK, Thomas JG, Williams DW. Biofilms and bacterial imbalances in chronic wounds: anti-Koch. Int Wound J 2010; 7: 169-175.
53. Donlan RM, Costerton JW. Biofilms: survival mechanisms of clinically relevant microorganisms. Clin Microbiol Rev 2002; 15: 167-193.
54. Percival SL, Bowler PG. Biofilms and their potential role in wound healing. Wounds 2004; 16: 234-240.
55. Gristina AG, Oga M, Webb LX, Hobgood CD. Adherent bacterial colonization in the pathogenesis of osteomyelitis. Science 1985; 228: 990-993.
56. 111 oxyquinolone. JAMA 1991; 266: 1246-1251.
57. James JA, Swogger E, Wolcott R, et al. Biofilms in chronic wounds. Wound Rep Reg 2008; 16: 37-44.
58. Potera C. Forging a link between biofilms and disease. Science 1999; 283: 1837-1839.
59. Reid G, Howard J, Gan BS. Can bacterial interference prevent infection? Trends Microbiol 2001; 9: 424-428.
60. Høiby N, Bjarnsholt T, Givskov M, Molin S, Ciofu O. Antibiotic resistance of bacterial biofilms. Int J Antimicrob Agents 2010; 35: 322-332.
61. Thomson CH. Biofilms: do they affect wound healing? Int Wound J 2010; 8: 63-67.
62. Dowd SE, Wolcott RD, Sun Y, McKeehan T, Smith E, Rhoads D. Polymicrobial nature of chronic diabetic foot ulcer biofilm infections determined using bacterial tag encoded FLX amplicon pyrosequencing (bTEFAP). PLoS One 2008; 3: e3326.
63. Fazli M, Bjarnsholt T, Kirketerp-Møller K, et al. Nonrandom distribution of Pseudomonas aeruginosa and Staphylococcus aureus in chronic wounds. J Clin Microbiol 2009; 47: 4084-4089.